Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 6Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Lung Neoplasms 2Leukemia, B-Cell 2Head and Neck Neoplasms 2Breast Neoplasms 2Vomiting 1Urinary Bladder Neoplasms 1Tracheal Diseases 1TP53 Y220C Mutation 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Salivary Gland Neoplasms 1Renal Insufficiency 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Nausea 1Myofibroma 1Mesothelioma 1

Interventions

relugolix 2telapristone acetate 1estradiol, norethindrone drug combination 1Uterine Artery Embolization 1Tablets 1Leuprolide 1LFA102 monoclonal antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Myofibroma × Tablets × Clear all
NCT03156127 2017-08-10

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Boryung Pharmaceutical Co., Ltd

Phase 1 Withdrawn

Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡